Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
Observational and mechanistic studies have suggested a possible relationship between treatment with metformin and decreased incidence of cancer in participants with type 2 diabetes. We extracted data for malignancies from the ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) randomised controlled clinical trials, in which the efficacy and/or safety of metformin was assessed in comparison with sulfonylureas and rosiglitazone.
Neoplasm occurrences were collected as adverse events in these studies. We reviewed and re-analysed the individual participant data in both studies for serious adverse events, malignancies reported as adverse events and related neoplasms of special interest.
In ADOPT, 50 participants (3.4%) on metformin and 55 (3.8%) on each of rosiglitazone and glibenclamide (known as glyburide in the USA and Canada) developed serious adverse event malignancies (excluding non-melanoma skin cancers). This corresponds to 1.03, 1.12 and 1.31 per 100 person-years, giving hazard ratios for metformin of 0.92 (95% CI 0.63–1.35) vs rosiglitazone and 0.78 (0.53–1.14) vs glibenclamide. In RECORD, on a background of sulfonylurea, 69 (6.1%) participants developed malignant neoplasms in the metformin group, compared with 56 (5.1%) in the rosiglitazone group (HR 1.22 [0.86–1.74]). On a background of metformin, 74 (6.7%) participants in the sulfonylurea group developed malignant neoplasms, compared with 57 (5.1%) in the rosiglitazone group (HR 1.33 [0.94–1.88]).
The malignancy rates in these two randomised controlled clinical trials do not support a view that metformin offers any particular protection against malignancy compared with rosiglitazone. However, they do not refute the possibility of a difference compared with sulfonylureas.
- Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305 CrossRef
- Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diab Care 29:254–258 CrossRef
- Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777 CrossRef
- Zakikhani M, Dowling R, Fantus IG et al (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273 CrossRef
- Smith U, Gale EAM (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699–1708 CrossRef
- Smith U, Gale EAM (2009) Lantus insulin: a possible link with cancer which requires further investigation. EASD webcast transcript. Available from http://webcast.easd.org/press/glargine/transcript.htm (accessed 10 August 2009)
- Holstein A, Nahrwold D, Hinze S, Egberts E-H (1999) Contra-indications to metformin therapy are largely disregarded. Diabet Med 16:692–696 CrossRef
- Kahn SE, Haffner SM, Heise MA et al, for the ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443 CrossRef
- Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125–2135 CrossRef
- ICH (2009) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guidelines. Available from www.ich.org/UrlGrpServer.jser?@_ID=276&@_TEMPLATE=254 (accessed 10 August 2009)
- Fisher LD, Lin DY (1999) Time-dependent covariates in the Cox proportional-hazards regression model. Ann Rev Public Health 20:145–157 CrossRef
- Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology 132:2208–2225 CrossRef
- Office for National Statistics (2004) Registrations of cancer diagnosed in 2004, England. Office for National Statistics, Series MB1: 35, London. Available from www.statistics.gov.uk/downloads/theme_health/MB1_35/MB1_No%2035_2004.pdf (accessed 10 August 2009).
- UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865 CrossRef
- UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853 CrossRef
- Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Volume 53, Issue 9 , pp 1838-1845
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Diabetes mellitus
- Industry Sectors
- Author Affiliations
- 1. ICM – Diabetes, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
- 2. Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, WA, USA
- 3. GlaxoSmithKline Research & Development, Harlow, UK
- 4. GlaxoSmithKline Research & Development, Greenford, UK
- 5. Endocrinology Research Unit, University of South Denmark, Odense, Denmark
- 6. Unit for Metabolic Medicine, King’s College London School of Medicine, London, UK